Literature DB >> 24300792

Fear of heights and visual height intolerance.

Thomas Brandt1, Doreen Huppert.   

Abstract

PURPOSE OF REVIEW: The aim of this review is, first, to cover the different aspects of visual height intolerance such as historical descriptions, definition of terms, phenomenology of the condition, neurophysiological control of gaze, stance and locomotion, and therapy, and, second, to identify warranted epidemiological and experimental studies. RECENT
FINDINGS: Vivid descriptions of fear of heights can be found in ancient texts from the Greek, Roman, and Chinese classics. The life-time prevalence of visual height intolerance is as high as 28% in the general population, and about 50% of those who are susceptible report an impact on quality of life. When exposed to heights, visual exploration by eye and head movements is restricted, and the velocity of locomotion is reduced. Therapy for fear of heights is dominated by the behavioral techniques applied during real or virtual reality exposure. Their efficacy might be facilitated by the administration of D-cycloserine or glucocorticoids.
SUMMARY: Visual height intolerance has a considerable impact on daily life and interpersonal interactions. It is much more frequent than fear of heights, which is defined as an environmental subtype of a specific phobia. There is certainly a continuum stretching from acrophobia to a less-pronounced visual height intolerance, to which the categorical distinction of a specific phobia does not apply.

Entities:  

Mesh:

Year:  2014        PMID: 24300792     DOI: 10.1097/WCO.0000000000000057

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  13 in total

1.  Visual height intolerance and acrophobia: clinical characteristics and comorbidity patterns.

Authors:  Hans-Peter Kapfhammer; Doreen Huppert; Eva Grill; Werner Fitz; Thomas Brandt
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-28       Impact factor: 5.270

2.  Behavioral realism and lifelike psychophysiological responses in virtual reality by the example of a height exposure.

Authors:  Joanna Kisker; Thomas Gruber; Benjamin Schöne
Journal:  Psychol Res       Date:  2019-09-13

3.  Dizziness and vertigo syndromes viewed with a historical eye.

Authors:  Doreen Huppert; Thomas Brandt
Journal:  J Neurol       Date:  2018-03-12       Impact factor: 4.849

4.  Modulation of human vestibular reflexes with increased postural threat.

Authors:  Brian C Horslen; Christopher J Dakin; J Timothy Inglis; Jean-Sébastien Blouin; Mark G Carpenter
Journal:  J Physiol       Date:  2014-06-27       Impact factor: 5.182

5.  Quantification of gait changes in subjects with visual height intolerance when exposed to heights.

Authors:  Roman Schniepp; Günter Kugler; Max Wuehr; Maria Eckl; Doreen Huppert; Sabrina Huth; Cauchy Pradhan; Klaus Jahn; Thomas Brandt
Journal:  Front Hum Neurosci       Date:  2014-12-04       Impact factor: 3.169

6.  A New Questionnaire for Estimating the Severity of Visual Height Intolerance and Acrophobia by a Metric Interval Scale.

Authors:  Doreen Huppert; Eva Grill; Thomas Brandt
Journal:  Front Neurol       Date:  2017-06-01       Impact factor: 4.003

7.  Susceptibility to Fear of Heights in Bilateral Vestibulopathy and Other Disorders of Vertigo and Balance.

Authors:  Thomas Brandt; Eva Grill; Michael Strupp; Doreen Huppert
Journal:  Front Neurol       Date:  2018-06-06       Impact factor: 4.003

8.  Balance control and anti-gravity muscle activity during the experience of fear at heights.

Authors:  Max Wuehr; Guenter Kugler; Roman Schniepp; Maria Eckl; Cauchy Pradhan; Klaus Jahn; Doreen Huppert; Thomas Brandt
Journal:  Physiol Rep       Date:  2014-02-18

9.  Visual exploration during locomotion limited by fear of heights.

Authors:  Günter Kugler; Doreen Huppert; Maria Eckl; Erich Schneider; Thomas Brandt
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

10.  Visual height intolerance and acrophobia: distressing partners for life.

Authors:  Hans-Peter Kapfhammer; Werner Fitz; Doreen Huppert; Eva Grill; Thomas Brandt
Journal:  J Neurol       Date:  2016-07-06       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.